Antiplatelet therapy after aspirin-induced upper gastrointestinal bleeding;Platehemmerbehandling ved tidligere gastrointestinal blødning forårsaket av acetylsalisylsyre

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 21, 2006, Pages 2802-2804

  Johansen, Maren ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ESOMEPRAZOLE; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR;

ALTERNATIVE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; MEDICAL PRACTICE; REVIEW; RISK FACTOR; THROMBOCYTE AGGLUTINATION;

ANTI-ULCER AGENTS; ASPIRIN; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS; TICLOPIDINE;

EID: 33750738048     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Statens legemiddelverk. Preparatomtale (SPC) Albyl-E. www.legemiddelverket.no/preparatomtaler (4.3.2005).
2. Norsk legemiddelhåndbok for helsepersonell. www.legemiddelhandboka. no/ (28.12.2005).
3. Patrono C, Garcia Rodriguez LA, Landolfi R et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
4. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7.
5. Lanas A, Ferrández A. Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 2002; 1: 245-52.
6. Statens legemiddelverk. Preparatomtale (SPC) Plavix. www. legemiddelverket.no/preparatomtaler (5.1.2005).
7. Ng FH, Wong SY, Chang CM et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 443-9.
8. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
9. CURE Study Investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme. Eur Heart J 2000; 21: 2033-41.
10. Peters JG, Mehta SR, Fox KAA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 2003; 108: 1682-7.
11. Serebruany VL, Steinhubl SR, Berger PB et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-22.
12. Chan FKL, Ching JYL, Hung LCT et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-44.
13. Statens legemiddelverk. Refusjon: Plavix (klopidogrel) ved akutt koronarsyndrom. www.legemiddelverket.no (10.12.2004).
14. Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003; 327: 1264.
15. Doggrell SA. Aspirin and esomeprazole are superior to clopidogrel in preventing recurrent ulcer bleeding. Expert Opin Pharmacother 2005; 6: 1253-6.
16. National Prescribing Centre. Prescribing antiplatelet drugs in primary care. MeReC Bulletin 2005; 15: 6.
17. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59: 1210-7.